Ocean Net Income From Continuing Ops from 2010 to 2024

OCEA Stock   0.71  0.02  2.74%   
Ocean Biomedical's Net Loss is decreasing over the years with stable fluctuation. Net Loss is expected to dwindle to about -905.7 K. From 2010 to 2024 Ocean Biomedical Net Loss quarterly data regression line had arithmetic mean of (4,602,916) and significance of  0.34. View All Fundamentals
 
Net Loss  
First Reported
2010-12-31
Previous Quarter
-862.6 K
Current Value
-905.7 K
Quarterly Volatility
16 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Ocean Biomedical financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Ocean Biomedical's main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.8 M, Selling General Administrative of 34.3 M or Total Revenue of 0.0, as well as many indicators such as Price To Sales Ratio of 0.0, Ptb Ratio of 3.44 or Days Sales Outstanding of 0.0. Ocean financial statements analysis is a perfect complement when working with Ocean Biomedical Valuation or Volatility modules.
  
Check out the analysis of Ocean Biomedical Correlation against competitors.
For information on how to trade Ocean Stock refer to our How to Trade Ocean Stock guide.

Latest Ocean Biomedical's Net Income From Continuing Ops Growth Pattern

Below is the plot of the Net Income From Continuing Ops of Ocean Biomedical over the last few years. It is Ocean Biomedical's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Ocean Biomedical's overall financial position and show how it may be relating to other accounts over time.
Net Income From Continuing Ops10 Years Trend
Pretty Stable
   Net Income From Continuing Ops   
       Timeline  

Ocean Net Income From Continuing Ops Regression Statistics

Arithmetic Mean(4,602,916)
Coefficient Of Variation(347.16)
Mean Deviation7,698,811
Median(232,000)
Standard Deviation15,979,285
Sample Variance255.3T
Range62.1M
R-Value(0.26)
Mean Square Error255.7T
R-Squared0.07
Significance0.34
Slope(945,867)
Total Sum of Squares3574.7T

Ocean Net Income From Continuing Ops History

2024-905.7 K
2023-862.6 K
2022-958.4 K
2021-62.3 M
2020-1.7 M

About Ocean Biomedical Financial Statements

Ocean Biomedical stakeholders use historical fundamental indicators, such as Ocean Biomedical's Net Income From Continuing Ops, to determine how well the company is positioned to perform in the future. Although Ocean Biomedical investors may analyze each financial statement separately, they are all interrelated. For example, changes in Ocean Biomedical's assets and liabilities are reflected in the revenues and expenses on Ocean Biomedical's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Ocean Biomedical. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Net Loss-862.6 K-905.7 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Ocean Biomedical is a strong investment it is important to analyze Ocean Biomedical's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Ocean Biomedical's future performance. For an informed investment choice regarding Ocean Stock, refer to the following important reports:
Check out the analysis of Ocean Biomedical Correlation against competitors.
For information on how to trade Ocean Stock refer to our How to Trade Ocean Stock guide.
You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ocean Biomedical. If investors know Ocean will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ocean Biomedical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(3.00)
Return On Assets
(6.82)
The market value of Ocean Biomedical is measured differently than its book value, which is the value of Ocean that is recorded on the company's balance sheet. Investors also form their own opinion of Ocean Biomedical's value that differs from its market value or its book value, called intrinsic value, which is Ocean Biomedical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ocean Biomedical's market value can be influenced by many factors that don't directly affect Ocean Biomedical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ocean Biomedical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Ocean Biomedical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ocean Biomedical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.